drugset / Trial / NCT03045497

Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Liver Cancer Receiving Transarterial Chemoembolization With Drug Eluting Beads

NCT03045497

NaSingle-groupOpen-labelDiagnostic

Summary

This pilot clinical trial compares the use of contrast-enhanced ultrasound to contrast-enhanced magnetic response imaging (MRI), the current clinical standard, in predicting treatment response in patients with liver cancer receiving transarterial chemoembolization with drug eluting beads. Comparing results of diagnostic procedures before and after transarterial chemoembolization may help doctors predict a patient's response to treatment and help plan the best treatment. It is not yet known if contrast-enhanced ultrasound works better than contrast-enhanced MRI in predicting treatment response in patients with liver cancer.

Timeline

Start
2012-12-12
Primary completion
2013-12-05
Completion
2013-12-05

Drugs

EvaluationDrugModalityDoseRoute
Background Definity Diagnostic / imaging agent Intravenous